7 Essential Pharma Stories for Life Sciences Leaders

From counterfeit vaccines to cancer drug pricing, today's news on pharmaceuticals demands constant vigilance. This press review delivers seven essential stories for life sciences leaders, combining media monitoring and media intelligence to track developments across Indian print publications. Print media monitoring by Press Monitor ensures you stay ahead of regulatory and safety developments. According to Press Monitor's tracking of Indian publications, here is what you need to know.

1. CDSCO Probes Counterfeit Abhayrab Vaccine

A front-page report in The Hindu says the Central Drugs Laboratory in Kasauli, Himachal Pradesh, flagged batch KE25Ol2 of the Abhayrab rabies vaccine as not of standard quality and misbranded after it failed a potency test. Delhi Police arrested four persons after seizing the suspect vials from an unlicensed residential premises on April 22, and the CDSCO has ordered a probe to establish who manufactured the vials and whether any patients received them. Indian Immunologicals Ltd. stated the batch was not produced by the company, while the Drugs Controller General of India has requested all State Drugs Controllers to maintain strict vigilance over the batch.

Why it matters: A counterfeit batch of the rabies vaccine Abhayrab has been seized in Delhi, raising serious concerns about drug safety across India.

Key detail: The Central Drugs Laboratory flagged batch KE25Ol2 as not of standard quality after it failed a potency test. Delhi Police arrested four persons, and the CDSCO has ordered a full probe to establish who manufactured the vials.

Source: The Hindu, front page

Next step: Monitor CDSCO updates and IIL's response for regulatory implications.

2. Palbociclib Not Interchangeable In Kerala HC Report

A front-page report in Morning Standard says the amicus curiae appointed by the Kerala High Court in a suo motu petition concerning the exorbitant prices of cancer drugs informed the court that Palbociclib can be used only for advanced breast cancer, while Ribociclib and Abemaciclib treat breast cancer at all stages, making them not interchangeable. The Regional Cancer Centre, Thiruvananthapuram, filed a statement noting similar progression-free survival but differing toxicity profiles. The court directed the National Cancer Institute, AITMS, Haryana, and the Chittaranjan National Cancer Institute, Kolkata, to file their respective affidavits.

Why it matters: The Kerala High Court is examining whether cancer drugs can be substituted, a decision that could reshape treatment protocols nationwide.

Key detail: The amicus curiae confirmed Palbociclib is for advanced breast cancer only, while Ribociclib and Abemaciclib treat all stages, making them not interchangeable.

Source: Morning Standard

Next step: Watch for the court's final order and its impact on drug interchangeability policies.

3. 29 Drug-Resistant TB Cases Found

A front-page report in Tribune says over 25,000 people were screened in 637 villages in Solan, India, during an intensive six-month campaign that detected 1,170 new tuberculosis cases, including 29 with multi-drug resistant tuberculosis. The Health Department has linked patients to government hospitals for free medication and follow-up check-ups, while family members are receiving preventive treatment to curb transmission.

Why it matters: Drug-resistant tuberculosis poses a growing public health threat, and early detection is critical to containment.

Key detail: Over 25,000 people were screened in 637 villages in Solan, detecting 1,170 new TB cases including 29 with multi-drug resistant tuberculosis.

Source: Tribune

Next step: Track government follow-up on free medication and preventive treatment distribution.

4. Tukaram Mundhe Faces Court Setbacks

A front-page report in Economic Times says Maharashtra's food and drugs regulator, led by FDA Commissioner Tukaram Mundhe, has been cracking down on hotels, eateries and pharma companies in Mumbai and Pune on 18 July 2026. The Bombay High Court has questioned the regulator's actions, including cancelling the licences of two pharma companies without natural justice, warning of contempt proceedings over eateries inside the Mumbai Cricket Association despite 88 percent compliance, and fining five lakh rupees after a Pune eatery's licence was suspended despite 98 percent compliance. The Maharashtra state government also pushed back after Mundhe's loose edible oil ban, with Chief Minister Devendra Fadnavis granting traders a year's reprieve to switch to packaged oil.

Why it matters: The Maharashtra FDA commissioner's aggressive enforcement actions are facing judicial scrutiny, signaling tighter checks on regulatory overreach.

Key detail: The Bombay High Court questioned licence cancellations without natural justice and warned of contempt proceedings over eatery enforcement.

Source: Economic Times

Next step: Observe how the court's interventions reshape food and drug enforcement in Maharashtra.

5. HRT May Lower Alzheimer's Risk

A front-page report in Financial Express says New studies indicate hormone replacement therapy given timely at menopause helps in better cognition and lower Alzheimer's risk. Dr Pakhee Aggarwal, senior consultant at Indraprastha Apollo Hospital in Delhi, explains that HRT benefits include relief from symptoms but carries risks like a small increase in breast cancer risk with longer use. The decision should be individualised based on a woman's health history and symptoms.

Why it matters: New research on hormone replacement therapy and cognitive health could influence treatment guidelines for millions of Indian women.

Key detail: Timely HRT at menopause shows better cognition and lower Alzheimer's risk, though longer use carries a small increase in breast cancer risk.

Source: Financial Express

Next step: Follow up with clinical guidelines updates from Indian medical bodies.

6. Preconception B12 Levels Affect Birth Defects

A front-page report in Financial Express says a new study highlights that both mothers' and fathers' vitamin B12 levels around the time of conception may influence the risk of birth defects in their children. Higher vitamin B12 levels in both parents were associated with fewer birth defects overall, including congenital heart defects. The report also covers research on diabetes health risks among women and men in India, higher mortality rates with drug-resistant bacteria across India, and zinc supplementation for children with sickle cell anaemia.

Why it matters: Research linking parental B12 levels to birth defects opens new avenues for preconception health strategies.

Key detail: Higher B12 levels in both parents were associated with fewer birth defects overall, including congenital heart defects.

Source: Financial Express

Next step: Watch for ICMR recommendations on B12 supplementation guidelines.

7. Rs 1,010.95 Crore Projects in Meghalaya

A front-page report in First India says Vice President CP Radhakrishnan will visit Meghalaya on September 7 to lay foundation stones for five projects worth Rs 1,010.95 crore. The projects include a 110-metre bridge over the Umngot River, the Phase II of the New Shillong Water Supply Scheme, and a 30-bedded AYUSH hospital. The largest project is the Rs 850.58 crore New Shillong Water Supply Scheme Phase II, designed to provide safe drinking water to New Shillong City.

Why it matters: Major infrastructure investment including a 30-bedded AYUSH hospital signals government commitment to traditional medicine infrastructure.

Key detail: Vice President CP Radhakrishnan will lay foundation stones for five projects, with the largest being the Rs 850.58 crore New Shillong Water Supply Scheme Phase II.

Source: First India

Next step: Monitor project timelines and AYUSH hospital development progress.

Closing question: Which of these developments will have the most impact on your sector in the coming quarter?